# NCT03931291 (NCT03931291)

> APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

No report yet. It can be ordered.

- Drugs tested: eprenetapopt plus azacitidine
- Indication: TP53-mutant AML or MDS following allogeneic stem-cell transplant

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03931291
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Aprea Therapeutics
- Conditions: Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Interventions: APR-246
- Enrollment: 33
- Primary outcome: To Assess Relapse-free Survival (RFS) in Patients With TP53 Mutated AML or MDS After Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT).

## Indexed commentary on NCT03931291 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03931291